ArticleThe Journal of antimicrobial chemotherapy2020
Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas' disease.
Article in The Journal of antimicrobial chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Discovery of Novel Inhibitors of Cruzain Cysteine Protease ofCurrent medicinal chemistry · 2024Pooled it
- Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay.Nature communications · 2024Trial
- Fluorination of amino-quinones enhances anti-RSC medicinal chemistry · 2026Article
- IID432, a parasite-selective topoisomerase II inhibitor, achieves rapid single-dose parasite clearance in a murine chronic Chagas model.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- High and Selective TrypanocidalMicroorganisms · 2026Article
- Human Histatin 5 Exerts Anti-Trypanosomal Activity AgainstInternational journal of molecular sciences · 2026Article
- Pyridyl-Imidazopyridine Derivatives Displaying Submicromolar Activity Against Trypanosoma cruzi.ChemMedChem · 2026Article
- Scalable Access to N‑Acylindole Linkages: Enabling the Synthesis of Antitrypanosomal Noncanonical Cyclic Peptides for Chagas Disease.Angewandte Chemie (International ed. in English) · 2026Article
- Identification of NovelDiseases (Basel, Switzerland) · 2026Article
- Parasitic diseases in heart transplantation: challenges of Toxoplasmosis and Chagas Disease.JHLT open · 2026Review
- MaternalbioRxiv : the preprint server for biology · 2026Article
- To Explore Potential Natural Inhibitors of Cysteine Proteases to Combat Human African Trypanosomiasis and Chagas Disease.Current medicinal chemistry · 2026Review
- A specific, stable, and accessible LAMP assay targeting the HSP70 gene ofMicrobiology spectrum · 2025Article
- Collaborative Synthesis for Neglected Diseases through the Open Synthesis Network: Structure-Activity Relationships of Arylaminopyrazoles as Chagas Disease Treatments.ACS infectious diseases · 2025Article
- Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion.PLoS neglected tropical diseases · 2025Article
- TrypPROTACs Unlocking New Therapeutic Strategies for Chagas Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Immunologic changes in the peripheral blood transcriptome of individuals with early-stage chronic Chagas cardiomyopathy: a cross-sectional study.Lancet regional health. Americas · 2025Article
- Transcriptomic analysis of benznidazole-resistant Trypanosoma cruzi clone reveals nitroreductase I-independent resistance mechanisms.PloS one · 2025Article
- Mannich Bases: Promising Scaffolds for the Treatment of Infectious Diseases.Current medicinal chemistry · 2025Review
- Achieving the Optimal AgO Concentrations to Modulate the Anti-Pharmaceutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent options for Chagas' disease treatment are restricted to benznidazole and nifurtimox. To the best of our knowledge, no study has ever compared their tolerance in adults in a non-endemic country.
objectivesTo compare the completion rates and drug tolerance in a cohort of patients treated according to current guidelines. PATIENTS AND
methodsWe analysed the medical records of all Chagas' disease patients aged 18 years or over who started antiparasitic treatment at the Geneva University Hospitals, Switzerland, from 2008 to 2016. We recorded treatment duration and all adverse events.
resultsWe included 176 patients, 92 and 84 of whom received benznidazole or nifurtimox, respectively. The overall treatment completion rate was 62.5%, without a significant difference between the groups (P=0.436). Most patients (89.8%) suffered at least one adverse event. Those receiving nifurtimox had more events (6.2 versus 3.5, P<0.001). Mucocutaneous symptoms predominated in the benznidazole group, whereas digestive symptoms were most frequent with nifurtimox. Neuropsychiatric events frequently occurred in both groups, most notably in patients receiving nifurtimox. Arthralgia, dyspnoea, sensitive neuropathy and pruritus were independent predictors of treatment interruption.
conclusionsCurrently recommended drug regimens for Chagas' disease are not well tolerated and entail frequent treatment discontinuation irrespective of the drug used. This highlights the need to improve treatment tolerance in adults with Chagas' disease with new therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.